The role of specific KRAS mutation types in response to treatment by EGFR inhibitors.

Authors
Publication date
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1200%2Fjco.2011.29...
      Last time updated on 25/10/2020